Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06727877

Predictive Diagnosis of Ulcero-Necrotizing EnteroColitis in Premature Babies Using an Artificial Intelligence Approach Based on Early Analysis of the Fecal Microbiota

Prematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neurodevelopmental morbidity.

Its onset is unpredictable and sudden, usually between 10 and 20 days of life, and requires immediate, aggressive management: hemodynamic support, fasting, systemic antibiotic therapy or even surgery.

Prevention is therefore essential, but systematic measures with proven efficacy (breastfeeding, early enteral feeding, multiple probiotics) are few and far between. What's more, these preventive measures cannot be modulated and adapted individually, since it is not possible to finely predict the risk of developing enterocolitis.

Thus, the use of a predictive diagnostic test for NEC would make it possible to identify high-risk premature babies and develop personalized preventive measures.

Changes in the digestive microbiota precede the onset of NEC, but it has not been possible to identify a reproducible and reliable microbial signature. As a result, the limited power of microbiota analysis and interpretation means that it cannot be used in practice to predict ECUN.

Our partner team (MEDiS) has developed a bioinformatics chain (RiboTaxa) to obtain the precise structure of complex microbial communities from direct metagenomic sequencing data. Stool samples from international cohorts (1562 samples, 208 preterm infants) were then mined to train a deep neural network and generate a predictive diagnostic test for NEC. In a local study (10 cases and 10 controls), the predictive diagnostic performance of this test was 90%, with the 1ère stool identified as "at risk" preceding NEC by 8 days (extremes 4 - 17 days), and the 2nde by 2 days (extremes 0-7 days). We would now like to test our predictive diagnostic technique on a larger number of premature babies in the AURA region.

1000 children included, 200 children tested (50 NEC - 150 controls)

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Necrotizing Enterocolitis (NEC) Digestive System Diseases Enterocolitis Enterocolitis, Necrotizing Gastroenteritis Gastrointestinal Diseases Healthy Control Intestinal Diseases

Age range

Up to 1 day

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Clermont-Ferrand, Clermont-Ferrand, France

Loading trial locations.

About this study

Systematic collection of stool (excluding meconium) from premature infants up to 21 days of age. Systematic analysis of the first two stools at the MEDiS laboratory: analysis of fecal microbiota by direct metagenomic sequencing (RiboTaxa), coupled with artificial intelligence (deep neural network previously trained on literature data). The test gives us a dichotomous response (yes/no) for each stool.

In the event of discordant analysis between the 2 stools (approximately 35% of cases in our preliminary study), a 3ème stool will be analyzed in order to classify the child as being at risk of NEC or not. The person performing these analyses will not be informed of the child's clinical evolution.

The diagnosis of NEC will be made by the clinician in charge of the child, according to the Bell classification.

Follow-up until return home or transfer to a peripheral center. A telephone call will be made to parents at 3 months of age, to ensure that no NECN has occurred after transfer to a peripheral center.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Child born prematurely (i.e. before 34 weeks of amenorrhea) in one of participating university hospitals and hospitalized in neonatal intensive care units of the AURA region's university hospitals
  • Child born outside CHU and transferred before 24h of life to the neonatal intensive care unit of one of thehospital participating in the study
  • Affiliated with a Social Security scheme

Exclusion criteria

  • Child whose guardians are protected by law (guardianship, curatorship, safeguard of justice)
  • Children whose parents are under 18 years of age
  • Refusal of parental authority to participate

Treatment and study plan

Ability of early digestive microbiota analysis (using artificial intelligence) to predict the occurrence of NEC diagnosed according to the Bell classification.

Diagnostic Test

The test gives us a dichotomous response (yes/no) for each stool. We will systematically analyze two stools per child, and in the event of a discrepancy, we will analyze a third to classify the child as being at risk of NEC or not.

The analysis model consists of a deep neural network that has been trained and optimized on data from international cohorts. In a local pilot study (N=20), it enabled accurate prediction for 90% of newborns.

Primary outcomes

  1. predictive diagnostic of NEC based on artificial intelligence analysis of fecal microbiota

    Time frame: before day 21

    percentage of prediction occurrence of NEC

Secondary outcomes

  1. predictive diagnostic of NEC as a function of newborn characteristics

    Time frame: before day 21

    percentage of predictive NEC according to newborn characteristics

  2. caracterization of microbiota in premature babies

    Time frame: before day 21

    measures how many types of species

  3. caracterization of microbiota in premature babies

    Time frame: before day 21

    percentage of different bacteria

  4. correlations between fecal microbiota and complications of prematurity (infectious, neurological, neurovegetative)

    Time frame: before day 21

    percentage of different bacteria according to the occurrence or non-occurrence of complications of prematurity (intraventricular hemorrhage, retinopathy, sepsis

Study contacts

Contact information is provided by the study sponsor or research team.

Lise Laclautre

CONTACT

[email protected]

334.73.754.963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: PECUNIA

Important dates

Study start
2025
Primary completion
2027
Study completion
2027
First posted
Dec 11, 2024
Registry last updated
Apr 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.